Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation

Journal of Neurophysiology

Volumn 92, Issue 6, 2004, Pages 3562-3574

  Nackley, A G ^a,c   Zvonok, A M ^b   Makriyannis, A ^b   Hohmann, A G ^a  

^a University of Georgia ^*  (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CARRAGEENAN; RIMONABANT; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; ANALGESIC AGENT; BORNANE DERIVATIVE; CANNABINOID; CANNABINOID RECEPTOR CB2, RAT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; INFLAMMATION; MALE; NERVE CELL EXCITABILITY; NERVE FIBER C; NOCICEPTION; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; TRANSCUTANEOUS NERVE STIMULATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; EDEMA; ELECTROSTIMULATION; NOCICEPTIVE RECEPTOR; NONMYELINATED NERVE; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTERIOR HORN CELL; SPRAGUE DAWLEY RAT;

ANALGESICS; ANIMALS; BORNANES; CANNABINOIDS; CARRAGEENAN; EDEMA; ELECTRIC STIMULATION; INFLAMMATION; MALE; NERVE FIBERS, UNMYELINATED; NOCICEPTORS; PIPERIDINES; POSTERIOR HORN CELLS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB2;

EID: 8644274638     PISSN: 00223077     EISSN: None     Source Type: Journal    
DOI: 10.1152/jn.00886.2003     Document Type: Article

References (87)

1. Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, and Vogel Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 375: 143-147, 1995.
2. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrie B, Rinaldi-Carmona M, Calandra B, Le Fur G, and Casellas P. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 237: 704-711, 1996.
3. Bridges D, Rice AS, Egertová, M, Elphick MR, Winter J, and Michael GJ. Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience 119: 803-812, 2003.
4. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, and Glass M. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396: 141-149, 2000.
5. Cabral GA and Mishkin EM. Delta-9-tetrahydrocannabinol inhibits macrophage protein expression in response to bacterial immunomodulators. J Toxicol Environ Health 26: 175-182, 1989.
6. Calignano A, La Rana G, Giuffrida A, and Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 394: 227-281, 1998.
7. Calignano A, La Rana G, and Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419: 191-198, 2001.
8. Chapman V. Functional changes in the inhibitory effect of spinal cannabinoid (CB) receptor activation in nerve injured rats. Neuropharmacology 41: 870-877, 2001.
9. Chapman V and Dickinson AH. Inflammation reveals inhibition of noxious responses of rat spinal neurons by carbamazepine. Neuroreport 8: 1399-1404, 1997.
10. Chapman V, Wildman MA, and Dickenson AH. Distinct electrophysiological effects of two spinally administered membrane stabilizing drugs, bupivacaine and lamotrigine. Pain 71: 285-295, 1997.
11. Clayton N, Marshall FH, Bountra C, and O'Shaughnessy CT. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96: 253-260, 2002.
12. Coghill RC, Mayer DJ, and Price DD. The roles of spatial recruitment and discharge frequency in spinal cord coding of pain: a combined electrophysiological and imaging investigation. Pain 53: 295-309, 1993.
13. Dougherty PM, Schwartz A, and Lenz FA. Responses of primate spinomesencephalic tract cells to intradermal capsaicin. Neuroscience 90: 1377-1392, 1999.
14. 35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci 12: 2079-2086, 2000.
15. Dubner R. Neuronal plasticity and pain following peripheral tissue inflammation or nerve injury. In: Proceedings of The World Congress on Pain, Pain Research and Clinical Management 5, edited by Bond M, Charlton E, and Woolf CJ. Amsterdam: Elsevier, 1986, p. 263-276.
16. Farquhar-Smith WP and Rice AS. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology 94: 507-513, 2001.
17. 2 receptors. Mol Pharmacol 48: 443-450, 1995.
18. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, and Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61, 1995.
19. Gerber G and Randic M. Participation of excitatory amino acid receptors in the slow excitatory synaptic transmission in the rat spinal dorsal horn in vitro. Neurosci Lett 106: 220-228, 1989.
20. Goutopoulos A and Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol Ther 95: 103-117, 2002.
21. Gracely RH, Lynch SA, and Bennett GJ. Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain 51: 175-194, 1992.
22. Guilbaud G, Kayser V, Benoist JM, and Gautron M. Modifications in the responsiveness of rat ventrobasal thalamic neurons at different stages of carrageenin-produced inflammation. Brain Res 385: 86-98, 1986.
23. Haley J, Ketchum S, and Dickenson A. Peripheral kappa-opioid modulation of the formalin response: an electrophysiological study in the rat. Eur J Pharmacol 191: 437-446, 1990.
24. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, and Fride E. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96: 14228-14233, 1999.
25. Harris J, Drew LJ, and Chapman V. Spinal anandamide inhibits nociceptive transmission via cannabinoid receptor activation in vivo. Neuroreport 11: 2817-2819, 2000.
26. Hedo G, Laird JMA, and Lopez-Garcia JA. Time-course of spinal sensitization following carrageenan-induced inflammation in the young rat: a comparative electrophysiological and behavioural study in vitro and in vivo. Neuroscience 92: 309-318, 1998.
27. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 121: 173-190, 2002.
28. 2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 308: 446-453, 2004.
29. Hohmann AG and Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 92: 1171-1175, 1999a.
30. Hohmann AG and Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 90: 923-931, 1999b.
31. Hohmann AG, Martin WJ, Tsou K, and Walker JM. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55.212-2. Life Sci 56: 2111-2118, 1995.
32. Hohmann AG, Tsou K, and Walker JM. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2. Neurosci Lett 257: 119-122, 1998.
33. Hohmann AG, Tsou K, and Walker JM. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J Neurophysiol 81: 575-583, 1999.
34. Honore P, Jaroslava B, and Jean-Marie B. Intraplantar morphine depresses spinal c-Fos expression induced by carrageenin inflammation but not by noxious heat. Br J Pharmacol 118: 671-680, 1996.
35. Hylden JL, Nahin RL, Traub RJ, and Dubner R. Effects of spinal kappa-opioid receptor agonists on the responsiveness of nociceptive superficial dorsal horn neurons. Pain 44: 187-193, 1991.
36. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, and Malan TP. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529-10533, 2003.
37. Kelly S and Chapman V. Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J Neurophysiol 86: 3061-3064, 2001.
38. Klegeris A, Bissonnette CJ, and McGeer PL. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 139: 775-786, 2003.
39. 9- tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action. Psychopharmacology (Berl) 143: 322-326, 1999.
40. Li J, Simone DA, and Larson AA. Windup leads to characteristics of central sensitization. Pain 79: 75-82, 1999.
41. Lynn AB and Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 268: 1612-1623, 1994.
42. Malan TP, Ibrahim MM, Makriyannis A, and Porreca F. CB2 cannabinoid receptors may produce peripheral analgesia by stimulating local release of endogenous opioids. Int Cannabinoid Res Soc Abstr 52, 2004.
43. Malan TP Jr, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, Porreca F, and Makriyannis A. CB(2) cannabinoid receptor-mediated peripheral antinociception. Pain 93: 239-245, 2001.
44. Malan TP Jr, Ibrahim MM, Vanderah TW, Makriyannis A, and Porreca F. Inhibition of pain responses by activation of CB2 cannabinoid receptors. Chem Phys Lipids 121: 191-200, 2002.
45. Martin WJ, Hohmann AG, and Walker JM. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci 16: 6601-6611, 1996.
46. Martin WJ, Tsou K, and Walker JM. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett 242: 33-36, 1998.
47. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, and Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564, 1990.
48. Mazzari S, Canella R, Petrelli L, Marcolongo G, and Leon AN. (2-Hydroxyethyl)-hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 300: 227-236, 1996.
49. McMahon SB and Wall PD. Receptive fields of rat lamina 1 projection cells move to incorporate a nearby region of injury. Pain 19: 235-247, 1984.
50. Mendell LM. Physiological properties of unmyelinated fibers projecting to the spinal cord. Exp Neurol 16: 316-332, 1966.
51. Munro S, Thomas KL, and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65, 1993.
52. 2 receptors suppresses inflammation-induced spinal Fos protein-expression and pain behavior. Neuroscience 119: 747-757, 2003a.
53. Nackley AG, Suplita RL, and Hohmann AG. A peripheral cannabinoid mechanism suppresses spinal Fos protein-expression and pain behavior in a rat model of inflammation. Neuroscience 117: 659-670, 2003b.
54. Nakatsuka T, Park JS, Kumamoto E, Tamaki T, and Yoshimura M. Plastic changes in sensory inputs to rat substantia gelatinosa neurons following peripheral inflammation. Pain 82: 39-47, 1999.
55. Neugebauer V and Schaible HG. Evidence for a central component in the sensitization of spinal neurons with joint input during development of acute arthritis in cat's knee. J Neurophysiol 64: 299-311, 1990.
56. Neumann S, Doubell TP, Leslie T, and Woolf CJ. Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature 384: 360-364, 1996.
57. Parolaro D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci 65: 637-644, 1999.
58. 2) receptor activation. Br J Pharmacol 140: 261-268, 2003.
59. Patrini G, Sacerdote P, Fuzio D, Manfredi B, and Parolaro D. Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP-55,940, a synthetic cannabinoid compound. J Neuroimmunol 80: 143-148, 1997.
60. Pertovaara A, Hamalainen MM, Kauppila T, and Panula P. Carrageenan-induced changes in spinal nociception and its modulation by the brain stem. Neuroreport 9: 351-355, 1998.
61. Price TJ, Helesic G, Parghi D, Hargreaves KM, and Flores CM. The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat. Neuroscience 120: 155-162, 2003.
62. Quartilho A, Heriberto P, Mata BS, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, and Malan P. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99: 955-960, 2003.
63. Reeh PW. Chemical excitation and sensitization of nociceptors. In: Cellular Mechanisms of Sensory Processing, edited by Urban I. Heidelberg, Germany: Springer-Verlag, 1994, p. 119-131.
64. Ren K, Hylden JL, Williams GM, Ruda MA, and Dubner R. The effects of a non-competitive NMDA receptor antagonist, MK-801, on behavioral hyperalgesia and dorsal horn neuronal activity in rats with unilateral inflammation. Pain 50: 331-344, 1992.
65. Rice AS, Farquhar-Smith WP, and Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 66: 243-256, 2002.
66. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, and Caput D. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240-244, 1994.
67. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Breliere JC, and Le Fur GL. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284: 644-650, 1998.
68. Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG, MacEwan DJ, and Scott RH. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40: 221-232, 2001.
69. Schmidt RF. Presynaptic inhibition in the vertebrate nervous system. Rev Physiol Biochem Pharmacol 63: 21-101, 1971.
70. Simone DA, Sorkin LS, Oh U, Chung JM, Owens C, LaMotte RH, and Willis, WD. Neurogenic hyperalgesia: central neural correlates in responses of spinothalamic tract neurons. J Neurophysiol 66: 228-246, 1991.
71. Sivilotti LG, Thompson SWN, and Woolf J. Rate of rise of the cumulative depolarization evoked by repetitive stimulation of small-caliber afferents is a predictor of action potential windup in rat spinal neurons in vitro. J Neurophysiol 69: 1621-1631, 1993.
72. Sokal DM, Elmes SJR, Kendall DA, and Chapman V. Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurons via activation of CB2 receptors in anesthetized rats. Neuropharmacology 45: 404-411, 2003.
73. Sorkin LS and Puig S. Neuronal model of tactile allodynia produced by spinal strychnine: effects of excitatory amino acid antagonists and μ-opiate receptor agonist. Pain 68: 283-292, 1996.
74. Sorkin LS, Puig S, and Jones DL. Spinal bicuculline produces hypersensitivity of dorsal horn neurons: effects of excitatory amino acid antagonists. Pain 77: 181-190, 1998.
75. Stanfa LC, Sullivan AF, and Dickenson AH. Alterations in neuronal excitability and the potency of spinal mu, delta and kappa opioids after carrageenan-induced inflammation. Pain 50: 345-354, 1992.
76. Strangman NM and Walker JM. Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol 82: 472-477, 1999.
77. Svendsen F, Rygh LJ, Hole K, and Tjolsen A. Dorsal horn NMDA receptor function is changed after peripheral inflammation. Pain 83: 517-523, 1999.
78. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, and Walker JM. Immunohistochemical distribution of cannabi noid CB1 receptors in the rat central nervous system. Neuroscience 83: 393-411, 1998.
79. Urban L and Randic M. Slow excitatory transmission in rat dorsal horn: possible mediation by peptides. Brain Res 290: 336-341, 1984.
80. Valk P, Verbakel S, Vankan Y, Hol S, Mancham S, Ploemacher R, Mayen A, Lowenberg B, and Delwel R. Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. Blood 90: 1448-1457, 1997.
81. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, and Stella N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23: 1398-1405, 2003.
82. Woolf CJ, Shortland P, and Sivilotti LG. Sensitization of high mechanothreshold superficial dorsal horn and flexor motor neurons following chemosensitive primary afferent activation. Pain 58: 141-155, 1994.
83. Yoshimura M and Jessell T. Amino acid-mediated EPSPs at primary afferent synapses with substantia gelatinosa neurones in the rat spinal cord. J Physiol 430: 315-335, 1990.
84. 2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17: 2750-2754, 2003.
85. Zhang Y, Yang Z, Gao X, and Wu G. The role of 5-hydroxytryptamine1A and 5-hydroxytryptamine1B receptors in modulating spinal nociceptive transmission in normal and carrageenan-injected rats. Pain 92: 201-211, 2001.
86. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, and Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96: 5780-5785, 1999.
87. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110, 1983.